FDA clears MiniMed Fit, MiniMed's first tubeless insulin pump
MiniMed said on November 16 that the FDA cleared MiniMed Fit, a tubeless patch pump worn up to seven days, days after Tandem won clearance for a tubeless Mobi.
Pulse, covering wearables and health sensors
, 3 min read
300 unitsinsulin capacity of the MiniMed Fit pump
What to know
- MiniMed Fit is cleared for people with type 1 and type 2 diabetes aged 7 and older, according to MiniMed and MedTech Dive.
- It can be worn for up to seven days and works with the Simplera Sync sensor and Abbott's Instinct sensor.
- MiniMed plans a phased US rollout in spring 2027; no price has been announced.
MiniMed, the diabetes device maker that separated from Medtronic earlier this year, said on Monday, November 16, that the US Food and Drug Administration had cleared MiniMed Fit, its first tubeless insulin pump. The pump sticks to the skin as a patch, holds 300 units of insulin and can be worn for up to seven days, according to the company's announcement and a report by MedTech Dive.
The clearance came one business day after Tandem Diabetes Care disclosed FDA clearance for a tubeless version of its Mobi pump. With both, the tubeless market that Insulet's Omnipod has led goes from one major player to three.
What MiniMed Fit is
MiniMed Fit is cleared for people with type 1 and type 2 diabetes aged 7 and older. It runs MiniMed's automated insulin delivery software, which adjusts insulin from continuous glucose monitor (CGM) readings. MedTech Dive reports it includes a meal detection algorithm that can add insulin when a mealtime dose is missed or underestimated. MiniMed's release names the automation SmartGuard and says it can give correction doses every five minutes.
The pump works with two all-in-one glucose sensors: MiniMed's own Simplera Sync and the Instinct sensor made by Abbott. In its release, MiniMed lists Simplera Sync at up to seven days of wear and Instinct at up to 15 days. It is controlled from a phone app on iOS and Android.
The seven-day figure has a condition. MiniMed's release says a full week of wear assumes a total daily dose under 42 units of insulin; people who use more will change the pump sooner.
How it compares
MiniMed's headline calls Fit the "world's first and only" tubeless pump with up to seven-day wear. Its own footnotes, and MedTech Dive, show where the comparison is drawn:
- Omnipod (Insulet) is worn for up to three days and holds 200 units, according to the release's footnotes.
- Tandem Mobi is also cleared for up to seven days of wear, MedTech Dive reports, but its insulin cartridge has to be changed more often. MiniMed's footnotes put that change at three days, with a 200-unit cartridge.
Tandem's tubeless Mobi replaces the tubed infusion set with a disposable on-body kit, so users can wear the same pump either way, MedTech Dive reports. Tandem plans a limited launch before full availability in the first half of 2027, according to William Blair analysts cited by the outlet. Leerink Partners analysts called it Tandem's "single most important commercial catalyst and growth driver."
When and how people can get it
MiniMed plans a phased US rollout in spring 2027, according to both sources. The company's release says an early customer experience phase starts before that, in its fourth fiscal quarter of 2027, and that Fit will be sold through the pharmacy channel. Tandem is taking the same route for its tubeless supplies. Neither company has announced a price.
MedTech Dive reports MiniMed has been building manufacturing capacity ahead of the launch. Chief executive Que Dallara told investors in September the company sees Fit as "a truly differentiated patch system."
Why it matters
Until now, Insulet's Omnipod has led the tubeless pump market, MedTech Dive reports. Two new seven-day options mean fewer device changes for many users and more competition on pharmacy pricing in 2027. They also widen the choice of sensor pairings: Fit runs with Abbott's Instinct, while Abbott has said its Libre Duo glucose-ketone sensor will work with other pumps. For people with type 2 diabetes, where CGM use is a growing focus (see Dexcom's CONNECT trial and Dexcom's latest results), a type 2 label from age 7 is part of the pitch. For what an FDA "clearance" does and does not mean, see our explainer on clearance, approval and De Novo.
This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.
Sources
- FDA Clears MiniMed Fit™ -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions, MiniMed via PR Newswire, Nov 16, 2026
- MiniMed gets FDA nod for tubeless insulin pump, MedTech Dive, Nov 16, 2026
- Tandem wins FDA clearance for tubeless automated insulin delivery system, MedTech Dive, Nov 16, 2026
FDA and health regulationWearablesGlucose and metabolic tech
Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.